ArticleNature communications2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The prevalence of Mycobacterium tuberculosis and rifampicin-resistance strains using GeneXpert-MTB/RIF assay in Ethiopia: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Developing an integrated medication event monitoring system and smartphone-based ecological momentary assessment delivery platform to identify real-time factors influencing TB treatment adherence in South Africa.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Burden of multidrug-resistant and extensively drug-resistant tuberculosis in China, India and Russia: estimates from the GBD 2023 study.Journal of thoracic disease · 2026Article
- Accuracy of the Phenotypic 1G Test to Detect Mycobacterium tuberculosis and Drug Resistance From Sputa in the US-Mexico Border.The Journal of infectious diseases · 2026Article
- Limited contribution of compensatory mutations to MDR/RR-TB clustering in Hunan Province, China: a population-based whole-genome sequencing study.Microbiology spectrum · 2026Article
- Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application.BMJ open respiratory research · 2026Review
- Impact of risk adjustment for drug-resistant types on tuberculosis patients' outcomes under China's innovative payment methods: a quasi-experimental study design.Infectious diseases of poverty · 2026Article
- Profiling of BDQ-induced transcriptome suggests amino acid metabolism and stress responses as alternate mechanisms contributing to BDQ tolerance inMicrobiology spectrum · 2026Article
- Tre-DST: A Drug Susceptibility Test forACS infectious diseases · 2026Article
- Global, regional, and national burden of tuberculosis, 1990-2050: a systematic comparative analysis based on retrospective cross-sectional of GBD 2021 and WHO surveillance systems.International journal of surgery (London, England) · 2026Article
- Multidrug resistant tuberculosis (MDR-TB) in Eritrea: a retrospective cohort analysis of mortality and associated factors (2013 - 2023).Frontiers in cellular and infection microbiology · 2026Article
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- Article
- Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova.BMJ global health · 2025Article
- Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025Review
- Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.Natural products and bioprospecting · 2025Review
- Development and hepatotoxicity of rifamycin derivatives.Expert opinion on drug metabolism & toxicology · 2025Review
- Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis.The Lancet. Global health · 2025Article
- Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.American journal of respiratory and critical care medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 5 countries.
Funding
Abstract
In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis). Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance. Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, 8.5) million DALYs, 44% (31, 54) of which accrued among TB survivors. We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis. RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries. While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors. The substantial long-term health impacts among those surviving RR-TB disease suggest the need for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.